Multigene RT-PCR Assay for Thyroid Cancer Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for thyroid cancer, particularly fine needle aspiration biopsy, often yield indeterminate or suspicious results, leading to unnecessary thyroidectomies, as existing preoperative clinical or imaging factors cannot reliably determine the need for surgical resection or lymph node dissection in patients with suspicious or indeterminate cytologic findings.
Innovation Solution
A real-time quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay using six novel candidate diagnostic and extent of disease markers (ECM1, TMPRSS4, ANGPT2, TIMP1, EFNB2, and EGFR) to differentiate between benign and malignant thyroid neoplasms, providing a multigene assay for improved diagnostic accuracy and risk stratification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If fine needle aspiration biopsy is used for thyroid nodule diagnosis, then the number of diagnostic thyroidectomies for benign neoplasms is reduced, but the method may be nondiagnostic or show indeterminate findings in 20% to 30% of cases
Solution Approach 1:
The diagnostic process is segmented into multiple stages: initial FNA biopsy followed by molecular marker testing (ECM1, TIMP1, EFNB2, EGFR) for indeterminate cases. This segmentation allows the system to handle different case types appropriately, using simple cytology for clear cases and adding molecular testing only when needed, thereby reducing unnecessary surgeries while maintaining high diagnostic accuracy.
Solution Approach 2:
Molecular markers serve as intermediaries between FNA biopsy results and surgical decision-making. These markers (ECM1, TIMP1, EFNB2, EGFR) provide additional diagnostic information for indeterminate cases, acting as a bridge that resolves uncertainty and guides appropriate clinical management without immediately proceeding to surgery.
2Reliability
If diagnostic thyroidectomy is recommended for all patients with suspicious or indeterminate FNA findings, then the risk of missing malignancy is reduced, but the number of unnecessary surgeries increases
Solution Approach 1:
Molecular marker testing is performed as a preliminary action before surgical intervention in indeterminate cases. By assessing ECM1, TIMP1, EFNB2, and EGFR expression levels beforehand, the system identifies high-risk patients who truly need surgery while avoiding unnecessary procedures in low-risk patients, thus maintaining high malignancy detection without increasing unnecessary surgeries.
Solution Approach 2:
The diagnostic approach changes from relying solely on cytologic parameters to incorporating molecular expression parameters (ECM1, TIMP1, EFNB2, EGFR). This parameter expansion allows better risk stratification, enabling clinicians to distinguish between indeterminate cases that require surgery versus those that can be managed conservatively, reducing unnecessary thyroidectomies while maintaining reliable malignancy detection.
3Adaptability or versatility
If preoperative molecular markers are used to stratify low-risk vs. high-risk patients, then the ability to guide surgical resection extent is improved, but the complexity of preoperative testing increases
Solution Approach 1:
The molecular testing panel is segmented into four specific markers (ECM1, TIMP1, EFNB2, EGFR) with defined roles in risk stratification. This segmentation makes the complex testing process manageable and interpretable, allowing clinicians to use standardized scoring systems based on these specific markers to guide surgical decisions regarding resection extent and lymph node dissection.
4Measurement precision
If a multigene RT-PCR assay is used to diagnose thyroid cancer, then diagnostic accuracy and risk stratification are improved, but the cost and complexity of the diagnostic process increase
Solution Approach 1:
Instead of testing all possible molecular markers, the system selectively tests a partial panel of four key markers (ECM1, TIMP1, EFNB2, EGFR) that have been identified as most useful for thyroid cancer diagnosis and risk stratification. This partial action approach maintains high diagnostic accuracy while avoiding the excessive complexity and cost of comprehensive genomic profiling.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multigene assay achieves high sensitivity and specificity in distinguishing malignant from benign thyroid neoplasms, correctly classifying 93% of tumors into low-risk or high-risk groups, reducing the need for unnecessary surgeries and aiding in selecting appropriate surgical treatments.
Implementation Method 1
A real-time quantitative reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assay using six novel candidate diagnostic and extent of disease markers (ECM1, TMPRSS4, ANGPT2, TIMP1, EFNB2, and EGFR) to differentiate between benign and malignant thyroid neoplasms
Data Source
AI summary
The present invention provides methods for diagnosing, providing a prognosis, and staging thyroid cancer, using panels of molecular markers that are differentially expressed in thyroid cancer. Also provided are methods to identify compounds that are useful for the treatment or prevention of thyroid cancer.